Engineering cardiac tissue in vivo from human adipose-derived stem cells

Area of Science:

• Regenerative Medicine
• Biomedical Engineering
• Stem Cell Biology

Background:

• Cardiac repair necessitates a reliable source of cardiomyocytes.
• Adipose-derived stem cells (ASC) are a potential source for regenerative therapies.
• In vivo tissue engineering requires cell sources and vascularization strategies.

Purpose of the Study:

• To assess the potential of human adipose-derived stem cells (ASC) to differentiate into cardiomyocytes in vivo.
• To evaluate the utility of co-implanting ASC with rat cardiomyocytes (rCM) in a vascularized tissue engineering chamber.
• To investigate ASC contribution to vascularization and overall engineered tissue growth.

Main Methods:

• Human ASC were co-implanted with neonatal rat cardiomyocytes (rCM) in a vascularized chamber.
• Control groups included rCM alone and ASC alone.
• Tissue constructs were analyzed after 6 weeks using immunostaining for human nuclei and cardiac markers.

Main Results:

• ASC differentiated into cardiomyocytes, smooth muscle cells, and adipocytes in vivo.
• Co-implantation (ASC-rCM) resulted in larger tissue constructs compared to rCM alone.
• Engineered cardiac muscle volume was significantly higher in ASC-rCM and rCM groups compared to ASC alone.
• Vascular volume was doubled in the ASC-rCM group compared to the rCM group.

Conclusions:

• Human ASC demonstrate plasticity and cardiomyogenic potential in vivo within a tissue engineering setting.
• Co-implantation with rCM promotes ASC differentiation into functional cardiomyocytes and enhances engineered tissue vascularization.
• ASC are a promising cell source for cardiac tissue engineering, contributing to both cardiomyocyte generation and improved vascular support.